Thursday, October 19
1:00pm – 2:00pm EST
Biologic cancer treatments have become incredibly important in oncology, but they can be expensive. Biosimilars are molecules manufactured to replicate the effects of biologics. They give patients and providers a choice and help to drive prices down through competition, but doctors, patients and caregivers need to understand what biosimilars are, what they can do, and the strengths and limits of this new frontier in medicine.
The online discussion was be led by John Snowden, the Director of Biosimilars at Amgen Canada, Inc., a biotechnology company based in Mississauga Ontario. He is a founding member and current Co-Chair for the newly formed industry trade association The Canadian Biosimilar Forum.
The presentation will be followed by a question-and-answer discussion.
Can’t attend? Be sure to register in order to have a copy of the slides as well as a YouTube recording of the webinar sent to you.
John Snowden, Director of Biosimilars at Amgen Canada Inc., obtained his Business degree from the University of Alberta, and has worked with biologic medicines for the last 17 years.
Please note that we have not been authorized to share this presentation’s slides via our SlideShare account.